Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
333 participants
INTERVENTIONAL
2012-01-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Double-blind Comparative Study of TAK-875
NCT01433393
Long-term Study of TAK-875
NCT01433406
Double Blind Comparative Study of TAK-875
NCT01585792
Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
NCT00949091
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
NCT01456195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAK-875 25 mg
TAK-875
TAK-875 50 mg
TAK-875
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAK-875
TAK-875
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria
2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Katori-shi, Chiba, Japan
Niihama-shi, Ehime, Japan
Chikushino-shi, Fukuoka, Japan
Fukuoka, Fukuoka, Japan
Onga-gun, Fukuoka, Japan
Yukuhashi-shi, Fukuoka, Japan
Hiroshima, Hiroshima, Japan
Chitose-shi, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Koga-shi, Ibaragi, Japan
Ushiku-shi, Ibaragi, Japan
Chigasaki-shi, Kanagawa, Japan
Kamakura-shi, Kanagawa, Japan
Minamata-shi, Kumamoto, Japan
Yatsushiro-shi, Kumamoto, Japan
Sasebo-shi, Nagasaki, Japan
Kashihara-shi, Nara, Japan
Okinawa-shi, Okinawa, Japan
Izumi-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Fujimi-shi, Saitama, Japan
Shimotsuga-gun, Tochigi, Japan
Komatsushima-shi, Tokushima, Japan
Bunkyo-ku, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Shibuya-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Toshima-ku, Tokyo, Japan
Shunan-shi, Yamaguchi, Japan
Ube-shi, Yamaguchi, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1124-1619
Identifier Type: REGISTRY
Identifier Source: secondary_id
JapicCTI-111605
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-875/OCT-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.